Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Cresco Labs (CRLBF) Asset Writedowns and Impairment (2020 - 2025)

Historic Asset Writedowns and Impairment for Cresco Labs (CRLBF) over the last 4 years, with Q3 2025 value amounting to $2.4 million.

  • Cresco Labs' Asset Writedowns and Impairment changed N/A to $2.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.6 million, marking a year-over-year change of. This contributed to the annual value of $2.3 million for FY2024, which is 9846.37% down from last year.
  • Latest data reveals that Cresco Labs reported Asset Writedowns and Impairment of $2.4 million as of Q3 2025.
  • Cresco Labs' Asset Writedowns and Impairment's 5-year high stood at $290.9 million during Q3 2021, with a 5-year trough of $24000.0 in Q4 2023.
  • Over the past 3 years, Cresco Labs' median Asset Writedowns and Impairment value was $9.0 million (recorded in 2025), while the average stood at $63.9 million.
  • Within the past 5 years, the most significant YoY rise in Cresco Labs' Asset Writedowns and Impairment was 6487826.09% (2021), while the steepest drop was 6487826.09% (2021).
  • Quarter analysis of 3 years shows Cresco Labs' Asset Writedowns and Impairment stood at $14.9 million in 2021, then plummeted by 99.84% to $24000.0 in 2023, then surged by 9754.17% to $2.4 million in 2025.
  • Its Asset Writedowns and Impairment was $2.4 million in Q3 2025, compared to $9.0 million in Q2 2025 and $216000.0 in Q1 2025.